Delivery Order SPE2DB22D3010-SPE2DB25FP0ZN

Award Date 11/22/24
Potential Completion Date 11/25/24
Potential Value $7.7K
Ultimate Awardee
Not listed
Federal Contract Vehicle
Set-Aside Type
No Set-Aside Used
Extent Competed
Full and Open Competition
Major Defense Program
Not listed
Pricing Type
Firm Fixed Price
Place of Performance
Conshohocken, PA 19428, USA
Solicitation Procedures
Negotiated Proposal / Quote
Number Of Offers Received
Not listed
Legislative Mandate
Not listed
National Interest Action
Not listed
Research Type
Not listed
Primary Consortia Member
Not listed
Similar Awards
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $8,491.43 firm-fixed-price delivery order is for the supply of 4 mg Ondansetron HCL tablets, a medication used to prevent nausea and vomiting. The award is part of a larger $999,999,999 Indefinite Delivery Contract (IDC) held by Amerisourcebergen with the DLA Troop Support Medical, which serves as a primary...
This federal contract award was issued by the Defense Logistics Agency (DLA) Troop Support Medical to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $14,005.08 Firm Fixed Price Delivery Order is for the supply of 4 mg Ondansetron HCL tablets, a medication used to prevent nausea and vomiting. This award is part of Amerisourcebergen's $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support Medical, which provides a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,791.65 firm-fixed-price delivery order is for the supply of Ondansetron ODT 4 mg tablets, a medication used to prevent nausea and vomiting. The award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that AmerisourceBergen holds with the DLA Troop Support Medical, which serves as a...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $3,554.56 firm-fixed-price delivery order is for the supply of 4 mg ondansetron hydrochloride tablets, a medication used to prevent nausea and vomiting. The contract has an ultimate completion date of March 17, 2025. Amerisourcebergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with the DLA Troop Support...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $9,910.38 firm fixed-price contract is for the delivery of Ondansetron ODT 4 mg tablets, a medication used to prevent nausea and vomiting. The contract is a delivery order under a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA Troop Support Medical. This...
This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $13,520.12 fixed-price delivery order is for the supply of 4,563,068,942 units of Ondansetron HCL 8 mg tablets, a medication used to prevent nausea and vomiting. The award is part of a larger Indefinite Delivery Contract (IDC) valued at $999,999,999 that Amerisourcebergen holds with the DLA Troop Support Medical...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $2,658.14 firm-fixed-price delivery order covers the supply of 4 mg Ondansetron HCl tablets, a medication used to prevent nausea and vomiting. The contract has a completion date of May 30, 2024 and does not have a set-aside designation, indicating open competition. AmerisourceBergen holds a significant...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $65,054.47 firm fixed-price delivery order is for the supply of 4 mg Ondansetron HCL tablets, a medication used to prevent nausea and vomiting. The contract has a completion date of June 11, 2024 and is not designated as a set-aside. AmerisourceBergen holds a $999,999,999 Indefinite Delivery Contract (IDC) with...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $17,701.76 firm-fixed-price delivery order is for the supply of 4 mg ondansetron hydrochloride tablets, a medication used to prevent nausea and vomiting. The contract has a completion date of July 9, 2024 and does not include any set-aside requirements. AmerisourceBergen holds a $999,999,999 Indefinite Delivery...
This federal contract award was issued by the Defense Logistics Agency (DLA) to AmerisourceBergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $1,335.75 firm fixed-price delivery order is for the provision of 4,563,518,646 units of 4 mg Ondansetron HCL tablets, a medication used to prevent nausea and vomiting. The contract has a completion date of February 2, 2024 and does not include a set-aside designation, indicating open competition....
  • SPE2DB22D3010
    Indefinite Delivery Contract
  • SPE2DB22D3010-SPE2DB25FP0ZN
    Delivery Order

This federal contract award was issued by the Defense Logistics Agency (DLA) to Amerisourcebergen Drug Corp, a major pharmaceutical distributor and healthcare solutions provider. The $7,658.30 firm fixed-price delivery order is for the supply of 4 mg Ondansetron HCL tablets, a medication used to prevent nausea and vomiting.

The award is associated with a larger Indefinite Delivery Contract (IDC) that Amerisourcebergen holds with the DLA, valued at $999,999,999 and running through November 2026. This IDC serves as a primary vehicle for providing a comprehensive range of pharmaceutical products and medical supplies to support military healthcare programs globally. The contract has no set-aside designation, indicating open competition.

In addition to the DLA contract, Amerisourcebergen also maintains a separate IDC with the Department of Justice Federal Bureau of Investigation, valued at $750,000 through May 2024, which covers similar medical products and prescription drugs. These IDCs enable efficient government procurement of essential pharmaceutical and medical supplies, serving the healthcare needs of military personnel, veterans, and other federal beneficiaries.

Generated 5/20/25, 2:22 PM